KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Medtronic (MDT) Cash from Financing Activities (2016 - 2025)

Historic Cash from Financing Activities for Medtronic (MDT) over the last 12 years, with Q4 2025 value amounting to -$395.0 million.

  • Medtronic's Cash from Financing Activities rose 2603.0% to -$395.0 million in Q4 2025 from the same period last year, while for Oct 2025 it was -$4.9 billion, marking a year-over-year increase of 491.8%. This contributed to the annual value of -$4.4 billion for FY2025, which is 200.0% up from last year.
  • Medtronic's Cash from Financing Activities amounted to -$395.0 million in Q4 2025, which was up 2603.0% from -$1.4 billion recorded in Q3 2025.
  • Medtronic's 5-year Cash from Financing Activities high stood at $3.0 billion for Q4 2022, and its period low was -$5.1 billion during Q2 2021.
  • For the 5-year period, Medtronic's Cash from Financing Activities averaged around -$1.4 billion, with its median value being -$1.2 billion (2021).
  • As far as peak fluctuations go, Medtronic's Cash from Financing Activities plummeted by 370937.5% in 2021, and later skyrocketed by 36095.24% in 2022.
  • Medtronic's Cash from Financing Activities (Quarter) stood at -$1.2 billion in 2021, then soared by 360.95% to $3.0 billion in 2022, then crashed by 102.99% to -$90.0 million in 2023, then crashed by 493.33% to -$534.0 million in 2024, then grew by 26.03% to -$395.0 million in 2025.
  • Its last three reported values are -$395.0 million in Q4 2025, -$1.4 billion for Q3 2025, and -$1.3 billion during Q2 2025.